Successful Treatment of Anabolic Steroid-induced Azoospermia with Human Chorionic Gonadotropin and Human Menopausal Gonadotropin
Overview
Authors
Affiliations
Objective: To document for the first time the successful treatment using human chorionic gonadotropin (hCG) and human menopausal gonadotropins (hMG) of anabolic steroid-induced azoospermia that was persistent despite 1 year of cessation from steroid use.
Design: Clinical case report.
Settings: Tertiary referral center for infertility.
Patient(s): A married couple with primary subfertility secondary to azoospermia and male hypogonadotropic hypogonadism. The husband was a bodybuilder who admitted to have used the anabolic steroids testosterone cypionate, methandrostenolone, oxandrolone, testosterone propionate, oxymetholone, nandrolone decanoate, and methenolone enanthate.
Intervention(s): Twice-weekly injections of 10,000 IU of hCG (Profasi; Serono) and daily injections of 75 IU of hMG (Humegon; Organon) for 3 months.
Main Outcome Measure(s): Semen analyses, pregnancy.
Result(s): Semen analyses returned to normal after 3 months of treatment. The couple conceived spontaneously 7 months later.
Conclusion(s): Steroid-induced azoospermia that is persistent after cessation of steroid use can be treated successfully with hCG and hMG.
Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis.
Mulawkar P, Maheshwari P, Gauhar V, Agrawal S, Mohammed T, Singh A J Hum Reprod Sci. 2024; 16(4):268-285.
PMID: 38322636 PMC: 10841926. DOI: 10.4103/jhrs.jhrs_90_23.
Al Hashimi M Andrologia. 2022; 54(11):e14576.
PMID: 36065528 PMC: 10078442. DOI: 10.1111/and.14576.
Endocrinopathies and Male Infertility.
Sengupta P, Dutta S, Karkada I, Chinni S Life (Basel). 2022; 12(1).
PMID: 35054403 PMC: 8779600. DOI: 10.3390/life12010010.
Esposito M, Licciardello G, Privitera F, Iannuzzi S, Liberto A, Sessa F Diagnostics (Basel). 2021; 11(8).
PMID: 34441242 PMC: 8393338. DOI: 10.3390/diagnostics11081307.
Treatments for people who use anabolic androgenic steroids: a scoping review.
Bates G, Van Hout M, Teck J, McVeigh J Harm Reduct J. 2020; 16(1):75.
PMID: 31888665 PMC: 6937954. DOI: 10.1186/s12954-019-0343-1.